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SUMMARY
Pharmacodynamic concepts should be applied to optimize 
antibiotic dosing regimens, particularly in the face of 
some multidrug resistant bacterial infections. Although 
the pharmacodynamics of most antibiotic classes used in 
the hospital setting are well described, guidance on how 
to select regimens and implement them into an antimi-
crobial stewardship program in one’s institution are more 
limited. The role of the antibiotic MIC is paramount in 
understanding which regimens might benefit from imple-
mentation as a protocol or use in individual patients. This 
review article outlines the pharmacodynamics of amino-
glycosides, beta-lactams, fluoroquinolones, tigecycline, 
vancomycin, and polymyxins with the goal of providing a 
basis for strategy to select an optimized antibiotic regimen 
in your hospital setting. 
Key words: Gram-negative bacteria, resistance, 
pharmacokinetics, MIC, prolonged infusion.
INTRODUCTION
Antibiotic resistant infections are a worldwide public health 
problem. As a result of emerging resistance in both Gram-
positive and Gram-negative bacteria, pathogens that 
remain susceptible to most currently available antibiotics 
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are diminishing and few antibiotics are in development to 
address these multidrug resistant (MDR) bacteria (1). Among 
Gram-positive bacteria, Staphylococcus aureus that are 
resistant to beta-lactams [i.e., methicillin-resistant S. aureus 
(MRSA)] can be found in as many as 50-60% of isolates 
(2). We are at the point clinically, whereby if S. aureus is a 
suspected cause of the infection, empiric therapy with an 
anti-MRSA antibiotic has become essential. On the Gram-
negative side, Pseudomonas aeruginosa continues to be 
a problematic pathogen due to its high prevalence in the 
hospital setting; however, the emergence of carbapenem 
resistant enterobacteriaceae (CRE) and carbapenem resistant 
Acinetobacter baumannii (CRAB) has rightly stolen headlines 
and are considered Urgent and Serious threats, respectively, 
by the Centers for Diseases Control (2,3). The lack of new 
antibiotics is particularly problematic in countries outside 
of the United States and European Union. Many of these 
countries have regulatory requirements that significantly 
delay the approval of new drugs, or in extreme cases, never 
make them available. As a result, the countries that often 
have the direst levels of MDR organisms seldom have the 
newest, most potent antibiotics in their armamentarium.
In addition to encouraging the continued development 
of new antibiotics, efforts must be made within the 
hospital setting to limit the emergence and spread of 
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MDR bacteria. Antimicrobial Stewardship Programs (ASPs) 
have become widely popular in the United States and 
Europe to address this unmet need (4). Such programs 
aim to manage antimicrobial use in the acute care setting 
through coordinated interventions designed to improve 
and measure appropriate use. ASPs, therefore, promote 
the selection of optimal antibiotic drug regimens including 
dosing, duration of therapy, and route of administration 
across the medical center. One component of ASPs is the 
consideration and implementation of antibiotic regimens 
based on pharmacodynamic concepts. Although the use of 
pharmacodynamics to design antibiotic dosing regimens, 
such as the continuous infusion of beta-lactams, has been 
widely reported in the literature, the strategic design and 
implementation of such programs as part of an ASP has been 
more elusive.
Herein, a brief review of antimicrobial pharmacodynamics 
is provided, followed by discussion of considerations and 
strategy regarding where implementation of these dosing 
strategies might provide the greatest benefits. 
PHARMACODYNAMICS: WHAT’S THE RIGHT DOSE?
Inappropriate antibiotic therapy is most often a result 
of delayed administration (i.e., waiting for culture or 
susceptibility results before initiating antibiotics or 
starting therapy as a result of a positive culture) or, 
more often, an underestimation of current trends in 
resistance. Regardless, the classification of an organism as 
“Susceptible”, “Intermediate”, or “Resistant” does not inform 
the prescriber of the ideal dose to use for the infection. 
Instead, the term “optimal antibiotic therapy” should be 
used and is meant to indicate that not only is the correct 
antibiotic selected, but also that the dosage is sufficient 
to obtain the maximal exposure threshold determined 
from pharmacodynamic studies. An interesting observation 
relevant to optimal antibiotic therapy is that the pathogen 
need not be “Susceptible” to the drug in question, as long as 
the exposure of the agent is sufficient to kill that organism.
Antimicrobial killing characteristics are dependent on 
both the concentration of drug in relation to the minimum 
inhibitory concentration (MIC) and the time that 
this exposure is maintained (Figure 1) (5). When the 
effect of concentration predominates over that of time, 
the antibiotic displays concentration-dependent effects 
that are significantly associated with an optimal free drug 
maximum concentration to MIC ratio (fCmax/MIC). When 
the effect of time is greater, the antibiotic displays time-
dependent effects, and bacterial outcomes are associated 
with free drug concentrations remaining above the MIC for a 
FIGURE  1. DEPICTION OF PHARMACODYNAMIC PARAMETERS OVER A CONCENTRATION TIME PROFILE
MIC: Minimum inhibitory concentration; Cmax/MIC: Maximum concentration to MIC ratio; AUC/MIC: Area under the curve to MIC ratio; T>MIC: Time 
above the MIC.
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defined portion of the dosing interval (fT>MIC). Additionally, 
antibiotics that have both concentration- and time-
dependent effects may observe killing that is associated with 
the free drug area under the curve to MIC ratio (ƒAUC/MIC). A 
summary of currently available antibiotic classes used in the 
acute care setting and their respective pharmacodynamic 
characteristics is provided in Table 1. At standard clinically 
relevant doses, concentration-dependent antimicrobials 
include the aminoglycosides, fluoroquinolones, and colistin. 
Time-dependent antimicrobials include the ơ-lactams, 
glycylcyclines, and vancomycin. 
AMINOGLYCOSIDES
The goal when dosing concentration-dependent 
antimicrobials is to achieve a total drug Cmax/MIC of 
approximately 10 to 12 or a total AUC/MIC of 150, both 
of which have been predictive of clinical success (6,7). 
Total drug exposure targets are reasonable here because 
the 3 currently available aminoglycosides (gentamicin, 
tobramycin, and amikacin) have low protein binding. As a 
result of pharmacodynamic studies, the traditional dosing 
regimen of 1 to 1.5mg/kg (gentamicin and tobramycin) or 
7.5mg/kg (amikacin) divided into two to three daily doses 
has been largely replaced with high-dose, extended-
interval regimens to achieve higher peak concentrations, 
resulting in improved clinical efficacy and, importantly, 
fewer nephrotoxic events. Nicolau and colleagues evaluated 
a once daily aminoglycoside dosing algorithm (7mg/kg daily, 
referred to as the Hartford Nomogram) in over 2000 adult 
patients and found a similar clinical response, but a reduced 
incidence of nephrotoxicity compared with historical data 
(1.2% vs. 3-5%) (8). In a simulation study, the probability of 
day 7 temperature resolution and nephrotoxicity between 
a once daily aminoglycoside regimen (10mg/kg every 
24h) compared with a twice daily (5mg/kg every 12h) 
dose was determined (9). At an MIC of 4mg/L (the current 
susceptibility breakpoint for gram-negative bacteria), the 
TABLE 1. SUMMARY OF ANTIBIOTICS THAT DISPLAY CONCENTRATION-DEPENDENT OR TIME-DEPENDENT KILLING 
CHARACTERISTIC AND THE REQUISITE PHARMACODYNAMIC EXPOSURE    
a Denotes common exposures based on free (f) drug concentrations, unless otherwise noted.
b Total drug exposure target. 
ANTIBIOTIC CLASS
Antibiotic
KILLING CHARACTERISTIC PHARMACODYNAMIC PARAMETER a
Aminoglycosides Concentration Dependent
amikacin, gentamicin, tobramycin fCmax/MIC > 10–12 (Gram-negatives)
ơ-lactams Time Dependent
carbapenems (doripenem, ertapenem, 
imipenem, meropenem)
40% fT>MIC (bactericidal activity, 
Gram-negatives)
cephalosporins (e.g., ceftriaxone, 
ceftazidime, cefepime)
 50%-70% fT>MIC (bactericidal activity, Gram-
negatives)
penicillins (e.g., oxacillin, ampicillin/
sulbactam, piperacillin/tazobactam)
50% fT>MIC (bactericidal activity, 
Gram-negatives)
Fluoroquinolones Concentration Dependent
ciprofloxacin, levofloxacin, AUC/MIC > 125 (Gram-negatives) b
moxifloxacin fAUC/MIC > 30–50 (Gram-positives)
Glycopeptides Concentration and Time 
Dependent
vancomycin AUC/MIC > 400 b
Glycylcycline Time Dependent 
  tigecycline
Polymyxins Concentration Dependent fAUC/MIC >12–48 (Pseudomonas and
polymyxin B, colistin (polymyxin E) Acinetobacter); corresponds with a Cssavg 
of 1–4mg/L when MIC=1mg/L
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twice daily dose had a 53.6% probability of temperature 
resolution compared with 79.7% for the once daily regimen. 
Additionally, nephrotoxicity of the twice daily dose was 
predicted to be significantly greater (24.6%) than the once 
daily regimen (<1%). The specific dose needed to obtain 
efficacy would therefore be dependent on the MIC of 
gram-negative bacteria in one’s clinical population and the 
patient’s renal function. If MICs are below 1mg/L, doses of 
3-5mg/kg once daily would be sufficient to obtain adequate 
exposure thresholds. The Hartford Nomogram dose of 
7mg/kg was designed to achieve optimal Cmax/MIC ratios 
for gentamicin and tobramycin at the MIC of 2mg/L, 
which was the MIC90 for P. aeruginosa at the institution 
at that time. In contrast, MICs of 4mg/L would require 
dosages of 10-14mg/kg daily to achieve the requisite 
pharmacodynamic targets. For patients with normal kidney 
function, these doses could be administered daily; however, 
for patients with moderate to severe renal failure, re-dosing 
should be delayed until concentrations fall below 1mg/L. 
Despite no change to the FDA labels, optimized, high-dose, 
extended-interval aminoglycoside dosing is now the most 
common dosing regimen employed for this antibiotic class (10).
BETA-LACTAMS
Beta-lactam antibiotics display time-dependent 
bactericidal activity, and in general, require fT>MIC for 
~50% of the dosing interval to achieve maximal effects; 
however, exposure can vary by the specific beta-lactam 
class. For instance, while the penicillin-based beta-
lactams are reported to require 50% fT>MIC, human and 
animal studies with cephalosporins suggest a requirement 
between 50% and 70% fT>MIC (11-13). The carbapenems 
(i.e., doripenem, ertapenem, imipenem, meropenem) are 
generally thought to achieve maximum bactericidal activity 
at ~40% fT>MIC (14). As a result, maximizing the time that 
concentrations remain above the MIC is the administration 
strategy. Various methods have been employed to 
maximize T>MIC, including giving higher dosages, 
administering the drugs more often, and prolonging the 
infusion time (either to 3-4 hours depending on room 
temperature stability or continuously over 24 hours). In 
general, the most effective way to optimize exposure, 
particularly against MDR gram-negative bacteria, to both 
increase the administered dose and prolong the infusion, 
thereby maintaining a concentration above higher MICs 
for the required bactericidal exposure time. This has been 
applied to beta-lactams such as cefepime, doripenem, 
and meropenem in numerous studies. In patients with 
normal renal function, 2 grams every 8 hours (each dose 
administered as a 3 or 4 hour prolonged infusions) dosing 
regimens achieve a high probability of treating organisms 
considered resistant with MICs of 8-16μg/ml and 
16-32μg/ml for doripenem/meropenem and cefepime, 
respectively, which is significantly greater than if the same 
dosage regimen were infused over the standard 30 minutes 
(15). Piperacillin/tazobactam dosing regimens can also be 
optimized by employing continuous or prolonged infusion 
administration. Kim and colleagues found that a 4.5g 
every 6 hour dose (with each dose infused over 3 hours) 
would achieve a similar pharmacodynamic exposure to 
the same daily dose (18.0g) administered as a continuous 
infusion, and both would have higher probabilities of 
target attainment than the standard 4.5g every 6 hour (30 
minute infusion) dose (16). Superior clinical outcomes were 
observed by Lodise and colleagues after implementing a 
piperacillin/tazobactam dosing regimen at their medical 
center where all piperacillin/tazobactam orders for 3.375g 
every 6 hours (30 minute infusion) were changed to 3.375g 
every 8 hours (4 hour prolonged infusions) (17). In patients 
with P. aeruginosa infections, the prolonged infusion had 
a lower 14-day mortality rate (12.2% vs. 31.6%, p=0.04) 
and shorter hospital stay (21 days vs. 38 days, p=0.02) 
that reached statistical significance when limited to 
critically-ill patients with an APACHE II score of ≥17. A 
number of clinical trials, mostly observational in design, 
have been conducted with continuous or prolonged 
infusion beta-lactams. A more thorough review of these 
studies is outside the scope of this paper, but can be found 
here (15,18). However, the most rigorous designed clinical 
studies comparing continuous infusion directly to the 
same beta-lactam administered as a standard 30 minute 
infusion include the BLING (Beta-Lactam INfusion Group) I 
and II studies, which were both multicenter, prospective, 
double-blind, randomized controlled trials (19,20). 
BLING I (19) enrolled 60 patients with severe sepsis who 
were randomized to continuous infusions of piperacillin/
tazobactam, meropenem or ticarcillin/clavulanate or the 
same drugs administered as an intermittent schedule. 
Clinical cure in the continuous infusion arm was 70% 
compared with only 43% (p=0.037) in the intermittent 
infusion treated patients.  T>MIC was also significantly 
greater in the continuous arm. BLING II (20) enrolled 432 
patients from 25 intensive care units across Australia, 
Asia and Europe. The larger study, however, did not find 
a difference in the primary endpoint, which was alive 
intensive care unit free days at day 28, a different and 
more challenging endpoint from the earlier trial. BLING 
II had notable limitations including a high prevalence 
of susceptible bacteria. In summary, most studies with 
continuous and prolonged infusion beta-lactams have 
demonstrated their greatest value in treating patients who 
are more critically ill and infected with higher MIC pathogens 
(i.e., less susceptible).
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FLUOROQUINOLONES
While fluoroquinolones are considered concentration-
dependent antibiotics, the maximum dose that can be 
safely administered is limited by dose-related central 
nervous system toxicity, thus a Cmax/MIC of 10 to 12 
cannot be achieved against many pathogens, and the time 
that concentrations are maintained above the MIC must 
be considered to maximize response. Therefore, in many 
pharmacodynamic studies, the bactericidal effect has been 
correlated with AUC/MIC (21). Against Gram-negative 
bacteria, a total AUC/MIC≥125 is most often quoted as being 
required for maximal effect, while Gram-positive bacteria, 
such as Streptococcus pneumoniae, require a free AUC/
MIC≥30 (22,23). It is important to consider, however, which 
fluoroquinolone was used in each pharmacodynamic study 
since protein binding varies substantially across agents and 
therefore, the total AUC/MIC targets may be different. In 
a study of 74 patients receiving ciprofloxacin for serious 
nosocomial infections predominantly due to Gram-negative 
bacteria, a total AUC/MIC below 125 was associated with 
a lower probability of clinical and microbiologic response 
(22). Additionally, an AUC/MIC above 125 and above 250 
were significantly associated with shorter median times 
to eradication (AUC/MIC<125:32 days, 125-250:6.6 days, 
>250:1.9 days, p<0.005). Correcting for ciprofloxacin protein 
binding of 40%, the ƒAUC/MIC threshold would be ~75. In 
another study, a levofloxacin total drug AUC/MIC exposure 
≥87 was prospectively determined to be predictive of 
eradication in 47 patients with nosocomial pneumonia (24). 
Correcting for levofloxacin protein binding, the ƒAUC/MIC 
target would be ~65, a value quite similar to the exposure 
required for ciprofloxacin against Gram-negative bacteria. 
Although fluoroquinolones are widely prescribed antibiotics, 
from a pharmacodynamic perspective, they are unable to 
achieve optimal pharmacodynamic exposure at standard 
dosages for not only bacteria considered resistant, but 
also a number of bacteria that the microbiology laboratory 
would classify as susceptible. This is a result of a higher 
than acceptable breakpoint used to define susceptibility for 
Gram-negatives (≤1mg/L for ciprofloxacin and ≤2mg/L for 
levofloxacin). Pharmacodynamic simulation studies suggest 
the proper breakpoints should be 0.25mg/L and 0.5mg/L, 
respectively, which would significantly increase resistance 
rates further at most hospitals, particularly against 
P. aeruginosa (25). As a result, even aggressive regimens 
such as ciprofloxacin 400mg every 8 hour and levofloxacin 
750mg every 24 hour have achieved low probabilities of 
attaining the required pharmacodynamic exposure against 
Gram-negative bacteria. The empiric use of the antibiotics 
as monotherapy for Gram-negative infections should be 
discouraged unless MIC data suggests adequate exposure 
is feasible. 
GLYCOPEPTIDES (VANCOMYCIN)
Although vancomycin success for Gram-positive infections 
has historically been thought to be associated with trough 
values, and thus T>MIC, contemporary data suggests 
that the AUC/MIC ratio best predicts outcomes for this 
time-dependent antibiotic (26). Studies in patients with 
pulmonary infections caused by S. aureus observed that 
vancomycin response was associated with a total drug 
AUC/MIC>345, and microbiological eradication was 
associated with an AUC/MIC>400. Alternative supportive 
data are provided by studies suggesting that clinical 
responses in S. aureus bacteremia were poor when the MIC 
was >1mg/L; at this MIC, the standard vancomycin dose (1g 
every 12 hours) does not attain these AUC/MIC exposures 
in patients with normal renal function. A consensus 
statement from the Infectious Diseases Society of America 
(IDSA), Society of Infectious Diseases Pharmacists (SIDP), 
and American Society of Health-Systems Pharmacist 
(ASHP) recommended that a loading dose of vancomycin 
be administered, particularly in critically ill patients, 
followed by doses of 30mg/kg daily to achieve troughs of 
15 to 20mg/L (26). However, in clinical scenarios where 
the vancomycin MIC was 2mg/L without clinical response, 
strong consideration for switching to an alternative 
antibiotic was suggested. The challenge with optimizing 
vancomycin based on the AUC/MIC ratio is 2 fold. First, 
to estimate an accurate AUC, multiple concentrations 
throughout the dosing interval are required; a trough alone 
or peak alone strategy to estimate AUC underestimated 
exposure by 23% and 14%, respectively (27). An approach 
that uses a single trough value, or multiple (at least 2 
samples over the dosing interval) concentrations, combined 
with Bayesian estimation of the AUC was significantly 
better at predicting the true AUC (~97% accurate). The 
second challenge lies with the MIC test itself. The error in 
accurate determination of the MIC is permitted to be 100% 
in either direction, meaning that an MIC of 1mg/L is the 
same as 0.5 and 2mg/L, thereby providing a 4 fold range in 
potential exposures. A patient who achieves a 24 hour AUC 
of 400mg*h/L infected with a bacteria reported as an MIC 
of 1mg/L may actually have an AUC/MIC exposure between 
200 and 800 based on variability of the MIC alone. As a 
result, the IDSA MRSA guidelines emphasize assessment of 
the patient response to therapy (28). Despite these well 
documented challenges, vancomycin remains the gold 
standard for the treatment of MRSA infections.
GLYCYLCYCLINES (TIGECYCLINE)
Tigecycline, the first member of the glycylcycline 
antibiotic class, portrays time-dependent activity, and 
the pharmacodynamic target most closely associated 
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with efficacy is the ƒAUC/MIC. In a murine pneumonia 
model, ƒAUC/MIC ratios of 2.17 and 8.78 were required 
to produce 1 and 2 log kill, respectively, against 
Acinetobacter spp (29). Using the data from the Phase 
3 clinical trial in treatment of hospital acquired 
pneumonia, a ƒAUC/MIC≥0.9 was associated with an 8 
fold higher probability of clinical success (30). After a 
loading dose of 100mg followed by 50mg every 12 hours, 
the steady state tigecycline AUC0-24 is ~4.7mg*h/L. 
Considering tigecycline protein binding is 80%, the 
fAUC0-24 would be ~0.94mg*h/L, which is similar to the 
median fAUC0-24 observed during the hospital acquired 
pneumonia study, 1.08mg*h/L (range: 0.35-4.02). As 
a result, standard doses of tigecycline achieve optimal 
exposure using the clinical pharmacodynamic threshold 
when the MIC is ~1mg/L, or ~0.5mg/L if the 1-log 
CFU reduction target is applied. The FDA susceptibility 
breakpoint is ≤2mg/L, whereas the EUCAST breakpoint is 
≤1mg/L. Unfortunately, limited clinical data are available 
to validate these observations, and variable outcomes 
with standard dosing tigecycline have been reported. 
A recent clinical trial of 55 patients with extensively 
drug-resistant A. baumannii bacteremia compared 
14 day mortality between a colistin/carbapenem and 
colistin/tigecycline combination (31). Patients received 
a standard tigecycline dosage. The colistin/tigecycline 
combination was independently associated with excess 
14 day mortality, but only in the subgroup of patients 
with a tigecycline MICs greater than 2mg/L. Because of 
poor clinical outcomes during the pneumonia registration 
studies, doubling the dose of tigecycline to a 200mg 
loading dose followed by 100mg every 12 hours has 
become clinically fashionable to treat MDR gram-
negative bacteria. This aggressive dose improved clinical 
cure (57.5% vs 30.4%, p=0.05) but not ICU mortality 
(48.4% vs 66.6%, p=0.14) in critically ill patients with 
CRAB and CRE infections (32). The majority of patients, 
however, still received tigecycline in combination with a 
second antibiotic such as colistin. 
POLYMYXINS
Polymyxin B and colistin (polymyxin E) have re-emerged 
into clinical practice because of their gram-negative activity 
against MDR organisms. Both antibiotics were developed 
during a time when pharmacodynamic studies were not 
required nor widely understood for new compounds; 
therefore, until a short time ago, package insert dosing 
recommendations were largely incorrect. Contemporary 
dosing regimens based on pharmacodynamic concepts have 
only recently begun to be understood, and the majority of 
available data has been contributed with colistin. Colistin 
displays concentration-dependent killing, and most 
studies suggest that the ƒAUC/MIC is best associated with 
bactericidal activity (33). Using the murine, thigh infection 
model, a ƒAUC/MIC of 12 was required to achieve a 2 log 
reduction against P. aeruginosa and A. baumannii strains. 
However, in the murine lung infection model, this ƒAUC/MIC 
exposure increased to 48 for a 1 log reduction; furthermore, 
2 of 3 A. baumannii strains tested never achieved this level 
of killing with any exposure tested. Considering colistin 
protein binding is approximately 50% in humans and 
estimating exposure over 24 hours, average steady state 
concentrations of 1 and 4mg/L correspond with ƒAUC/
MIC ratios of 12 and 48, respectively, when the colistin 
MIC is 1mg/L. Notably, colistin induced nephrotoxicity is 
concentration dependent and disproportionally increases 
with concentrations greater than 2.5mg/L. It should 
therefore become quickly apparent to the reader that the 
exposures required for efficacy significantly overlap with 
those that produce toxicity. Moreover, these required 
exposures are at an MIC of only 1mg/L; greater exposures 
are proportionally required for higher MICs. At the time of 
writing, the Clinical Laboratory Standards Institute (CLSI) 
and European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) were in discussions to harmonize 
colistin breakpoints. EUCAST defines susceptibility against 
P. aeruginosa at ≤4mg/L, and against A. baumannii and 
Enterobacteriaceae at ≤2mg/L. CLSI uses ≤2mg/L for the 
non-fermenting gram-negatives, but has no breakpoint 
defined for enterobacteriaceae. Based on contemporary 
pharmacokinetic data from Garonzik and colleagues (34), 
the European Medicines Agency (EMA) approved updated 
dosing suggestions for patients with varying degrees of 
renal function. This was followed by recommendations from 
the US Food and Drug Administration (FDA). A summary of 
these new dosing recommendations is provided in Table 2. 
An ensuing simulation study compared the EMA and FDA 
dosing recommendations with standard physician dosing 
(35). Both EMA and FDA doses resulted in greater average 
steady-state concentrations compared with physician 
selected doses, and EMA dosing provided the highest 
average concentrations across the creatinine clearance 
(CrCL) ranges. However, recommended dosing regimens 
from both agencies were able to provide a high probability 
of steady-state concentrations above 2mg/L when CrCL was 
≥80 ml/min. Therefore, caution is advised in using colistin 
as monotherapy when patients have good kidney function, 
MICs above 1mg/L, or both.
Although studies are still pending, polymyxin B is assumed 
to have a similar pharmacodynamic profile to colistin in that 
a ƒAUC/MIC of ~12 is required for 2 log CFU reductions (33). 
However, unlike colistin, polymyxin B is not a prodrug, thus 
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conversion into an active form is not required and the active 
drug component is immediately available. Subsequently, a 
loading dose of polymyxin B should achieve an active peak 
concentration immediately. When used in combination 
with larger daily doses, the ƒAUC/MIC can more easily be 
maximized. Current dosing recommendations for polymyxin 
B max out at 1.5 to 2.5mg/kg per day. However, a recent 
pharmacokinetic study in 24 patients demonstrated that 
a loading dose of 2.5mg/kg as a 2 hour infusion, followed 
by 1.5mg/kg every 12 hours as 1 hour infusions, would 
achieve a total daily AUC of ~50mg*h/L in approximately 
90% of patients (36). This exposure would be sufficient to 
obtain the ƒAUC/MIC target of 12 up to MICs of 2mg/L. 
Notably, polymyxin B clearance is not significantly affected 
by reductions in creatinine clearance, so aggressive 
dosage adjustments in this population are not required. A 
retrospective study by Nelson and colleagues (37) in patients 
with bloodstream infections due to carbapenem-resistant 
gram-negative rods observed that receipt of polymyxin 
B daily doses <1.3mg/kg was significantly associated with 
30-day mortality (OR=1.58; 95% CI 1.05 to 1.81; P=0.04). 
Furthermore, patients with renal impairment made up 82% 
of those receiving reduced polymyxin B doses. 
While the above data with colistin and polymyxin B are 
promising to guide optimal dosing, adaptive resistance 
remains a challenge. An in vitro pharmacodynamic study 
with several A. baumannii clinical isolates demonstrated 
significant regrowth of the total population, due to 
the emergence of adaptive resistance in all strains (38). 
This occurred even in the presence of aggressive dosing 
regimens (i.e., simulating free steady-state average 
concentrations of 3mg/L). Adaptive resistance to the 
polymyxins has also been described with P. aeruginosa and 
Enterobactericeae. As a result, optimal dosing of polymyxins 
is encouraged, but unlikely to result in promising clinical 
response when administered alone, and combination 
therapy is routinely recommended.
THE VALUE OF THE MIC
A common theme from the above review of pharmacodynamic 
concepts for all antibiotics is the importance of MIC. When 
determining an optimized dosing regimen to implement in 
the hospital setting, the ASP should consider local resistance 
rate trends. Furthermore, several studies have stressed 
the importance of institution specific data. While general 
susceptibility patterns can be identified from a hospital 
antibiogram, details on the MIC distributions of organisms 
are frequently absent. 
True antibiotic MIC testing is uncommonly conducted by most 
microbiology laboratories because it is more labor intensive 
and costly than automated (Vitek II™, Microscan™, etc.) 
susceptibility testing alone. Additionally, most prescribers 
have not received training to properly interpret the MIC. For 
these reasons, the microbiology laboratory typically only 
conducts breakpoint testing, which is synonymous with 
MIC testing but over only a small range of dilutions around 
the susceptibility and resistance breakpoints. For example, 
if an antibiotic’s susceptibility and resistance breakpoints 
are ≤8mg/L and ≥32mg/L, respectively, most automated 
systems will only test these concentrations. If the bacteria 
do not grow at 8mg/L, then “susceptibility” is reported. It 
cannot be determined, however, if the MIC is 8mg/L (i.e., 
borderline susceptible) or much lower (e.g., 0.5mg/L). 
Likewise, if the organism grows at both concentrations (8 
and 32mg/L), then it is reported as resistant, but clearly 
TABLE 2. UPDATED US FOOD AND DRUG ADMINISTRATION (FDA) AND EUROPEAN MEDICINES AGENCY (EMA) 
DOSING RECOMMENDATIONS FOR INTRAVENOUS COLISTIMETHATE BY CREATININE CLEARANCE RANGE   
CBA: colistin base activity (1mg of CBA = 2.4mg of colistimethate sodium = 30,000 IU; each colistimethate sodium vial contains 150mg CBA); MIU: million 
international units
a FDA expressed doses in mg/kg of CBA, using actual body weight except in obese individuals, where the dosage should be based on ideal body weight. 
Doses are divided into 2-3 doses per day.  No recommendation for a loading dose is made. 
b EMA expresses doses in MIU, which have been converted to mg of CBA for this table.  Doses are divided into 2-3 doses per day.  The EMA recommends 
a loading dose of 9 MIU (~300mg CBA) in critically ill patients.
c EMA indicates that daily doses up to 12 MIU (~400mg CBA) may be required for patients with good renal function. 
CREATININE CLEARANCE (ML/MIN)
US FDA
DAILY DOSEa
EMA
DAILY DOSEb
≥80 2.5-5mg CBA/kg 9 MIU (~300mg CBA)c
50 to <80 2.5-3.8mg CBA/kg 9 MIU (~300mg CBA)c
30 to <50 2.5mg CBA/kg 5.5-7.5 MIU (~183–250mg CBA)
10 to <30 1mg CBA/kg
(or 1.5mg CBA/kg every 36 hours)
4.5-5.5 MIU (~150-183mg CBA)
<10 NA 3.5 MIU (~117mg CBA)
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the organism may have a MIC of 32mg/L and potentially be 
treated with a higher than standard dose of the antibiotic, or 
the MIC may be much higher (e.g., 256mg/L), in which case 
it would not be possible to obtain the required bactericidal 
exposure without significantly increasing the risk of toxicity 
to the patient. MIC data are most useful when considering 
antibiotic pharmacodynamics because drug exposure is 
always referenced to the MIC when deciding how much and 
over what dosing interval to administer an antibiotic.
MIC testing can be conducted using various methods: 
broth microdilution, macrodilution, agar dilution, Etest® 
(BioMérieux, Durham, NC, USA), a type of diffusion test 
using gradient technology, and finally with some automated 
systems. The BD Phoenix™ Automated Microbiology System 
(BD Diagnostics, Sparks, MD, USA) and Vitek® 2 (BioMérieux, 
Durham, NC, USA) will also provide MIC results for an 
antibiotic/bacteria combination, but only over a few dilution 
ranges. For example, cefepime MICs for gram-negatives on 
the BD Phoenix™ system test from 0.5 to 16mg/L, which 
again would not inform the provider if an organism is 
potentially treatment with a higher dose/prolonged infusion 
at 32mg/L. When feasible, the use of broth microdilution or 
Etest is preferred to collect data on MIC distributions locally 
(by hospital or by unit), and can also be used for individual 
patients with MDR infections to help optimize antibiotic 
therapy, as both of these methodologies will provide for a 
larger MIC range to be tested.
IMPLEMENTING OPTIMIZED REGIMENS BY THE ASP
ASPs can take two different approaches to optimizing the use 
of an antibiotic. The traditional approach is to focus on the 
antibiotic itself; each time it is prescribed, that antibiotic 
is being optimized for that individual patient. The second 
is to approach the treatment of the infection itself using 
the most optimal strategy. With respect to implementing 
an optimized antibiotic dosing regimen in the institution, 
the latter strategy holds more merit. Before determining 
which antibiotic and dosing regimen to apply optimization 
to, it is critical to understand what the most likely causative 
pathogens are for the infection (e.g., ventilator associated 
pneumonia) and the MICs for these most causative bacteria.
The ventilator associated pneumonia clinical pathway at 
our hospital was instituted after collection of 8 months 
of bacteria surveillance data and MIC testing (39). 
Pharmacodynamic models were employed based on the 
most frequent causative pathogen for which MIC data were 
available, P. aeruginosa, to determine the choice of antibiotic 
and dosage regimen that would provide the greatest 
likelihood of obtaining its bactericidal pharmacodynamic 
exposure. Both continuous and prolonged infusion regimens 
as well as standard dosages were evaluated against the 
P. aeruginosa population. Due to increasing resistance in 
certain ICUs at our hospital, high-dose prolonged infusion 
regimens of cefepime or meropenem (2g every 8 hours 
as 3 hour infusions) were required to achieve optimal 
exposure, as these regimens would obtain a high likelihood 
of attaining pharmacodynamic exposure against isolates 
with MICs up to 32 and 16mg/L, respectively. In addition, 
tobramycin 7mg/kg once daily was advocated due to 
the frequency of multi-drug resistant organisms and the 
MIC90 for the P. aeruginosa population remaining at 2mg/L. 
Fluoroquinolones were strongly discouraged and reserved for 
patients unable to get aminoglycosides. Finally, a high dose 
vancomycin protocol was initiated aiming for trough values 
in the range of 15-20 μg/ml to cover for MRSA. After the 
protocol was initiated, we learned that our MRSA population 
predominantly had vancomycin MICs of 1.5 to 2mg/L. As a 
result, we now allow the prescriber to change therapy to 
linezolid if a patient with MRSA is not improving by day 3 of 
high-dose vancomycin therapy. These dosing regimens were 
protocolized in the ICUs using a computerized provider order 
set. Education was conducted for all providers, nurses, and 
pharmacists on the background/justification of the program 
and when to use it. 
After 12 months of use, data were collected to evaluate the 
impact (both clinical outcomes as well as compliance) of 
the clinical pathway. Compliance was nearly 100%, and 94 
patients were treated for ventilator associated pneumonia 
during that time.  Compared with the 74 patients used as 
historical controls, patients treated by the clinical pathway 
with cefepime or meropenem optimized dosing regimens had 
lower infection-related mortality (8.5% vs 21.6%, p=0.029), 
were more likely to receive an antibiotic with activity against 
the causative pathogen empirically (71.6%, vs 48.6%, p=0.007), 
had less MDR superinfections (9.6% vs 27.0%, p=0.006) and 
less infection related length of hospital stay (10.5 vs 23 days, 
p<0.001). An economic analysis observed approximately 
$40,000 (US$) savings per patient treated on the clinical 
pathway (40). This program is still a mandatory protocol in 
our ICUs, although we continue to make adjustments to 
our antibiotics and dosing regimens after screening MICs 
every couple of years. More recently, a prolonged infusion 
piperacillin/tazobactam regimen (4.5g q6h as a 3 hour 
infusion) has been implemented across our health system 
based on MIC data, contemporary pharmacokinetics, and the 
use of smart pumps across the system.
For the above clinical pathway, implementation was solely in 
the ICUs, which made education and monitoring easier. We 
also focused our optimization strategy around beta-lactams, 
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aminoglycosides and vancomycin, as these antibiotics were 
most appropriate for the causative pathogens observed in 
ventilator associated pneumonia. Agents such as polymyxin 
B and tigecycline are, fortunately, rarely required at our 
hospital due to few CRAB and CRE organisms. However, should 
this be different at another hospital, dosage selection and 
implementation should follow the same strategy as described 
above, which would include first, an understanding of MIC 
distributions for your population, followed by implementation 
of the most optimal dosing regimen to cover most of these 
pathogens. A follow up evaluation after a defined period of 
time (or number of cases treated) is paramount to ensuring 
compliance and outcomes are in line with expectations.  A 
critical but common mistake, however, would be to simply 
implement an optimized dosing regimen that has been 
described in the literature or used at another hospital without 
consideration of your local epidemiology, as outcomes may be 
largely different.
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